抗不整脈薬の世界市場規模・現状・予測2021年-2027年

QYResearchが発行した調査報告書(QY21JNE1820)
◆英語タイトル:Global Anti-Arrhythmic Drug Market Size, Status and Forecast 2021-2027
◆商品コード:QY21JNE1820
◆発行会社(リサーチ会社):QYResearch
◆発行日:2021年6月(※2024年版があります。お問い合わせください。)
◆ページ数:120
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査資料では、抗不整脈薬の世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(経口、非経口)、用途別市場規模(病院、在宅医療、専門診療所、その他)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。
・市場概要
・抗不整脈薬の市場動向
・企業の競争状況、市場シェア
・抗不整脈薬の種類別市場規模(経口、非経口)
・抗不整脈薬の用途別市場規模(病院、在宅医療、専門診療所、その他)
・抗不整脈薬の北米市場規模2016-2027(アメリカ、カナダ)
・抗不整脈薬の欧州市場規模2016-2027(ドイツ、フランス、イギリス等)
・抗不整脈薬のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・抗不整脈薬の中南米市場規模2016-2027(メキシコ、ブラジル)
・抗不整脈薬の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(Pfizer、Hikma Pharmaceuticals、Baxter、Aurobindo Pharma、Zydus Cadila、Wockhardt、Teva Pharmaceutical、Novartis、Mylan、Sun Pharmaceutical Industries、Fresenius Kabi、GSK、Lupin、Vintage Labs、Aurobindo Pharma、AstraZeneca、Dr. Reddy’s Laboratories、Johnson & Johnson Services)
・結論
【レポートの概要】

It is a class of drugs used to suppress abnormal heart rhythms (arrhythmia), such as atrial fibrillation, atrial flutter, ventricular tachycardia, and ventricular fibrillation.

Market Analysis and Insights: Global Anti-Arrhythmic Drug Market
The global Anti-Arrhythmic Drug market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Anti-Arrhythmic Drug market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Anti-Arrhythmic Drug market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Anti-Arrhythmic Drug market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Anti-Arrhythmic Drug market.

Global Anti-Arrhythmic Drug Scope and Market Size
Anti-Arrhythmic Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Anti-Arrhythmic Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Oral
Parenteral

Segment by Application
Hospitals
Homecare
Specialty Clinics
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Pfizer
Hikma Pharmaceuticals
Baxter
Aurobindo Pharma
Zydus Cadila
Wockhardt
Teva Pharmaceutical
Novartis
Mylan
Sun Pharmaceutical Industries
Fresenius Kabi
GSK
Lupin
Vintage Labs
Aurobindo Pharma
AstraZeneca
Dr. Reddy’s Laboratories
Johnson & Johnson Services

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Anti-Arrhythmic Drug Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Oral
1.2.3 Parenteral
1.3 Market by Application
1.3.1 Global Anti-Arrhythmic Drug Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Homecare
1.3.4 Specialty Clinics
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Anti-Arrhythmic Drug Market Perspective (2016-2027)
2.2 Anti-Arrhythmic Drug Growth Trends by Regions
2.2.1 Anti-Arrhythmic Drug Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Anti-Arrhythmic Drug Historic Market Share by Regions (2016-2021)
2.2.3 Anti-Arrhythmic Drug Forecasted Market Size by Regions (2022-2027)
2.3 Anti-Arrhythmic Drug Industry Dynamic
2.3.1 Anti-Arrhythmic Drug Market Trends
2.3.2 Anti-Arrhythmic Drug Market Drivers
2.3.3 Anti-Arrhythmic Drug Market Challenges
2.3.4 Anti-Arrhythmic Drug Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Anti-Arrhythmic Drug Players by Revenue
3.1.1 Global Top Anti-Arrhythmic Drug Players by Revenue (2016-2021)
3.1.2 Global Anti-Arrhythmic Drug Revenue Market Share by Players (2016-2021)
3.2 Global Anti-Arrhythmic Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Anti-Arrhythmic Drug Revenue
3.4 Global Anti-Arrhythmic Drug Market Concentration Ratio
3.4.1 Global Anti-Arrhythmic Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Anti-Arrhythmic Drug Revenue in 2020
3.5 Anti-Arrhythmic Drug Key Players Head office and Area Served
3.6 Key Players Anti-Arrhythmic Drug Product Solution and Service
3.7 Date of Enter into Anti-Arrhythmic Drug Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Anti-Arrhythmic Drug Breakdown Data by Type
4.1 Global Anti-Arrhythmic Drug Historic Market Size by Type (2016-2021)
4.2 Global Anti-Arrhythmic Drug Forecasted Market Size by Type (2022-2027)

5 Anti-Arrhythmic Drug Breakdown Data by Application
5.1 Global Anti-Arrhythmic Drug Historic Market Size by Application (2016-2021)
5.2 Global Anti-Arrhythmic Drug Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Anti-Arrhythmic Drug Market Size (2016-2027)
6.2 North America Anti-Arrhythmic Drug Market Size by Type
6.2.1 North America Anti-Arrhythmic Drug Market Size by Type (2016-2021)
6.2.2 North America Anti-Arrhythmic Drug Market Size by Type (2022-2027)
6.2.3 North America Anti-Arrhythmic Drug Market Size by Type (2016-2027)
6.3 North America Anti-Arrhythmic Drug Market Size by Application
6.3.1 North America Anti-Arrhythmic Drug Market Size by Application (2016-2021)
6.3.2 North America Anti-Arrhythmic Drug Market Size by Application (2022-2027)
6.3.3 North America Anti-Arrhythmic Drug Market Size by Application (2016-2027)
6.4 North America Anti-Arrhythmic Drug Market Size by Country
6.4.1 North America Anti-Arrhythmic Drug Market Size by Country (2016-2021)
6.4.2 North America Anti-Arrhythmic Drug Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Anti-Arrhythmic Drug Market Size (2016-2027)
7.2 Europe Anti-Arrhythmic Drug Market Size by Type
7.2.1 Europe Anti-Arrhythmic Drug Market Size by Type (2016-2021)
7.2.2 Europe Anti-Arrhythmic Drug Market Size by Type (2022-2027)
7.2.3 Europe Anti-Arrhythmic Drug Market Size by Type (2016-2027)
7.3 Europe Anti-Arrhythmic Drug Market Size by Application
7.3.1 Europe Anti-Arrhythmic Drug Market Size by Application (2016-2021)
7.3.2 Europe Anti-Arrhythmic Drug Market Size by Application (2022-2027)
7.3.3 Europe Anti-Arrhythmic Drug Market Size by Application (2016-2027)
7.4 Europe Anti-Arrhythmic Drug Market Size by Country
7.4.1 Europe Anti-Arrhythmic Drug Market Size by Country (2016-2021)
7.4.2 Europe Anti-Arrhythmic Drug Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Anti-Arrhythmic Drug Market Size (2016-2027)
8.2 Asia-Pacific Anti-Arrhythmic Drug Market Size by Type
8.2.1 Asia-Pacific Anti-Arrhythmic Drug Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Anti-Arrhythmic Drug Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Anti-Arrhythmic Drug Market Size by Type (2016-2027)
8.3 Asia-Pacific Anti-Arrhythmic Drug Market Size by Application
8.3.1 Asia-Pacific Anti-Arrhythmic Drug Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Anti-Arrhythmic Drug Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Anti-Arrhythmic Drug Market Size by Application (2016-2027)
8.4 Asia-Pacific Anti-Arrhythmic Drug Market Size by Region
8.4.1 Asia-Pacific Anti-Arrhythmic Drug Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Anti-Arrhythmic Drug Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Anti-Arrhythmic Drug Market Size (2016-2027)
9.2 Latin America Anti-Arrhythmic Drug Market Size by Type
9.2.1 Latin America Anti-Arrhythmic Drug Market Size by Type (2016-2021)
9.2.2 Latin America Anti-Arrhythmic Drug Market Size by Type (2022-2027)
9.2.3 Latin America Anti-Arrhythmic Drug Market Size by Type (2016-2027)
9.3 Latin America Anti-Arrhythmic Drug Market Size by Application
9.3.1 Latin America Anti-Arrhythmic Drug Market Size by Application (2016-2021)
9.3.2 Latin America Anti-Arrhythmic Drug Market Size by Application (2022-2027)
9.3.3 Latin America Anti-Arrhythmic Drug Market Size by Application (2016-2027)
9.4 Latin America Anti-Arrhythmic Drug Market Size by Country
9.4.1 Latin America Anti-Arrhythmic Drug Market Size by Country (2016-2021)
9.4.2 Latin America Anti-Arrhythmic Drug Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Anti-Arrhythmic Drug Market Size (2016-2027)
10.2 Middle East & Africa Anti-Arrhythmic Drug Market Size by Type
10.2.1 Middle East & Africa Anti-Arrhythmic Drug Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Anti-Arrhythmic Drug Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Anti-Arrhythmic Drug Market Size by Type (2016-2027)
10.3 Middle East & Africa Anti-Arrhythmic Drug Market Size by Application
10.3.1 Middle East & Africa Anti-Arrhythmic Drug Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Anti-Arrhythmic Drug Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Anti-Arrhythmic Drug Market Size by Application (2016-2027)
10.4 Middle East & Africa Anti-Arrhythmic Drug Market Size by Country
10.4.1 Middle East & Africa Anti-Arrhythmic Drug Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Anti-Arrhythmic Drug Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Anti-Arrhythmic Drug Introduction
11.1.4 Pfizer Revenue in Anti-Arrhythmic Drug Business (2016-2021)
11.1.5 Pfizer Recent Development
11.2 Hikma Pharmaceuticals
11.2.1 Hikma Pharmaceuticals Company Details
11.2.2 Hikma Pharmaceuticals Business Overview
11.2.3 Hikma Pharmaceuticals Anti-Arrhythmic Drug Introduction
11.2.4 Hikma Pharmaceuticals Revenue in Anti-Arrhythmic Drug Business (2016-2021)
11.2.5 Hikma Pharmaceuticals Recent Development
11.3 Baxter
11.3.1 Baxter Company Details
11.3.2 Baxter Business Overview
11.3.3 Baxter Anti-Arrhythmic Drug Introduction
11.3.4 Baxter Revenue in Anti-Arrhythmic Drug Business (2016-2021)
11.3.5 Baxter Recent Development
11.4 Aurobindo Pharma
11.4.1 Aurobindo Pharma Company Details
11.4.2 Aurobindo Pharma Business Overview
11.4.3 Aurobindo Pharma Anti-Arrhythmic Drug Introduction
11.4.4 Aurobindo Pharma Revenue in Anti-Arrhythmic Drug Business (2016-2021)
11.4.5 Aurobindo Pharma Recent Development
11.5 Zydus Cadila
11.5.1 Zydus Cadila Company Details
11.5.2 Zydus Cadila Business Overview
11.5.3 Zydus Cadila Anti-Arrhythmic Drug Introduction
11.5.4 Zydus Cadila Revenue in Anti-Arrhythmic Drug Business (2016-2021)
11.5.5 Zydus Cadila Recent Development
11.6 Wockhardt
11.6.1 Wockhardt Company Details
11.6.2 Wockhardt Business Overview
11.6.3 Wockhardt Anti-Arrhythmic Drug Introduction
11.6.4 Wockhardt Revenue in Anti-Arrhythmic Drug Business (2016-2021)
11.6.5 Wockhardt Recent Development
11.7 Teva Pharmaceutical
11.7.1 Teva Pharmaceutical Company Details
11.7.2 Teva Pharmaceutical Business Overview
11.7.3 Teva Pharmaceutical Anti-Arrhythmic Drug Introduction
11.7.4 Teva Pharmaceutical Revenue in Anti-Arrhythmic Drug Business (2016-2021)
11.7.5 Teva Pharmaceutical Recent Development
11.8 Novartis
11.8.1 Novartis Company Details
11.8.2 Novartis Business Overview
11.8.3 Novartis Anti-Arrhythmic Drug Introduction
11.8.4 Novartis Revenue in Anti-Arrhythmic Drug Business (2016-2021)
11.8.5 Novartis Recent Development
11.9 Mylan
11.9.1 Mylan Company Details
11.9.2 Mylan Business Overview
11.9.3 Mylan Anti-Arrhythmic Drug Introduction
11.9.4 Mylan Revenue in Anti-Arrhythmic Drug Business (2016-2021)
11.9.5 Mylan Recent Development
11.10 Sun Pharmaceutical Industries
11.10.1 Sun Pharmaceutical Industries Company Details
11.10.2 Sun Pharmaceutical Industries Business Overview
11.10.3 Sun Pharmaceutical Industries Anti-Arrhythmic Drug Introduction
11.10.4 Sun Pharmaceutical Industries Revenue in Anti-Arrhythmic Drug Business (2016-2021)
11.10.5 Sun Pharmaceutical Industries Recent Development
11.11 Fresenius Kabi
11.11.1 Fresenius Kabi Company Details
11.11.2 Fresenius Kabi Business Overview
11.11.3 Fresenius Kabi Anti-Arrhythmic Drug Introduction
11.11.4 Fresenius Kabi Revenue in Anti-Arrhythmic Drug Business (2016-2021)
11.11.5 Fresenius Kabi Recent Development
11.12 GSK
11.12.1 GSK Company Details
11.12.2 GSK Business Overview
11.12.3 GSK Anti-Arrhythmic Drug Introduction
11.12.4 GSK Revenue in Anti-Arrhythmic Drug Business (2016-2021)
11.12.5 GSK Recent Development
11.13 Lupin
11.13.1 Lupin Company Details
11.13.2 Lupin Business Overview
11.13.3 Lupin Anti-Arrhythmic Drug Introduction
11.13.4 Lupin Revenue in Anti-Arrhythmic Drug Business (2016-2021)
11.13.5 Lupin Recent Development
11.14 Vintage Labs
11.14.1 Vintage Labs Company Details
11.14.2 Vintage Labs Business Overview
11.14.3 Vintage Labs Anti-Arrhythmic Drug Introduction
11.14.4 Vintage Labs Revenue in Anti-Arrhythmic Drug Business (2016-2021)
11.14.5 Vintage Labs Recent Development
11.15 Aurobindo Pharma
11.15.1 Aurobindo Pharma Company Details
11.15.2 Aurobindo Pharma Business Overview
11.15.3 Aurobindo Pharma Anti-Arrhythmic Drug Introduction
11.15.4 Aurobindo Pharma Revenue in Anti-Arrhythmic Drug Business (2016-2021)
11.15.5 Aurobindo Pharma Recent Development
11.16 AstraZeneca
11.16.1 AstraZeneca Company Details
11.16.2 AstraZeneca Business Overview
11.16.3 AstraZeneca Anti-Arrhythmic Drug Introduction
11.16.4 AstraZeneca Revenue in Anti-Arrhythmic Drug Business (2016-2021)
11.16.5 AstraZeneca Recent Development
11.17 Dr. Reddy’s Laboratories
11.17.1 Dr. Reddy’s Laboratories Company Details
11.17.2 Dr. Reddy’s Laboratories Business Overview
11.17.3 Dr. Reddy’s Laboratories Anti-Arrhythmic Drug Introduction
11.17.4 Dr. Reddy’s Laboratories Revenue in Anti-Arrhythmic Drug Business (2016-2021)
11.17.5 Dr. Reddy’s Laboratories Recent Development
11.18 Johnson & Johnson Services
11.18.1 Johnson & Johnson Services Company Details
11.18.2 Johnson & Johnson Services Business Overview
11.18.3 Johnson & Johnson Services Anti-Arrhythmic Drug Introduction
11.18.4 Johnson & Johnson Services Revenue in Anti-Arrhythmic Drug Business (2016-2021)
11.18.5 Johnson & Johnson Services Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

...

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 抗不整脈薬の世界市場規模・現状・予測2021年-2027年(Global Anti-Arrhythmic Drug Market Size, Status and Forecast 2021-2027)]についてメールでお問い合わせはこちらでお願いします。